NCT07273409: PANTODON

Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not

Recruiting now NA Last updated 22 January 2026

What this trial tests

NA trial testing Debulking surgery in Pancreatic Neuroendocrine Tumor in 200 participants. Currently enrolling.

Timeline

9 January 2026

Primary endpoint
31 May 2033

31 May 2033

Quick facts

Lead sponsor	Uppsala University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	9 January 2026
Primary completion	31 May 2033
Estimated completion	31 May 2033
Sites	4 locations across Sweden

Drugs / interventions tested

• Debulking surgery

Conditions studied

• Pancreatic Neuroendocrine Tumor — all drugs for Pancreatic Neuroendocrine Tumor →

Sponsor

Uppsala University

Who can join

18 and older, any sex, with Pancreatic Neuroendocrine Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pancreatic neuroendocrine tumours (pan-NETs) are neoplasms arising from the endocrine cells of the pancreas. Although pan-NET are quite rare, the incidence is on the rise and together with other abdominal neuroendocrine tumours an approximate incidence in Sweden would be 850 patients per year extrapolating from Norwegian data. Pan-NET are divided into symptomatic hormone producing tumours (such as insulinomas/glucagonomas/VIPomas) or non-functioning tumours that often are asymptomatic. As early symptoms often are lacking in non-functioning-pan-NET, many patients present with distant metastases and are thus beyond a curative surgical approach at the time of diagnosis. Metastatic non-functioning pan-NETs present a significant challenge and the optimal management remains a subject of debate.

This is a prospective, two armed, parallel, randomised, controlled, international multi-centre study, aiming to investigate if a near-total tumour debulking (intervention) in metastatic (stage 4) GI-WHO grade 1-2 pan- NET, with or without oncologic treatment, is superior to oncologic treatment alone (control), with regards to overall survival, health-related quality of life, participant performance status, time until hospitalisation, adverse event characteristics and cost in the short and long term.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.